Pan European Networks - Horizon 2020 - page 175

important, in addition to consistently involving civil society across the
research lifecycle, from agenda setting to results’ validation and policy input.
European partnerships help improve and strengthen the co-operation
among all stakeholders, including health authorities, insurers, health
professionals, researchers, trade unions, employers and patients. It is
crucial that all relevant stakeholders streamline their efforts and improve
health services to respond to the growing burden of chronic diseases,
demographic changes and the ageing population.
Multistakeholder partnerships such as the European Innovation
Partnership on Active and Healthy Ageing and the EIT Health KIC play a
very important role by working to overcome the fragmentation of different
healthcare systems. Fragmentation can only be tackled by bringing
together partners from health organisations, patients’ associations,
business and industry, education, research, healthcare providers and
insurance companies.
The legislation further states that ‘emphasis will
also be placed on engaging all health
stakeholders – including patients and patient
organisations, and health and care providers –
in order to develop a research and innovation
agenda that actively involves citizens and
reflects their needs and expectations.’ The
ECDA welcomes these mentions of chronic
diseases and stakeholder involvement in the
Horizon 2020 Regulation.
H2020 impact
To optimise the programme’s contribution to
tackling chronic diseases, the ECDA believes
that Horizon 2020 should prioritise and
target the root causes of diseases such
as socioeconomic variables and health
determinants and foster projects to combat
health inequalities. The ECDA also believes
Horizon 2020 should focus on the ‘health in
all policies’ approach and health promotion
to identify factors that influence individual
behaviour and social norms.
The research and innovation framework
programme should strengthen links and
common solutions involving both health and
research authorities and stakeholders, as well as
address the effectiveness and cost-effectiveness
of prevention and treatment of chronic diseases,
including co-morbidities,e-health solutions and
innovative measures; such action will contribute
to developing new public health tools from
primary to palliative care.
Horizon 2020 should also ensure availability of
comparable datasets/registries on chronic
diseases’ incidence, prevalence and outcomes
to support evidence-based policy making, as
well as identify gaps in research such as
shared risk factors and co-morbidities; such
action can contribute towards overcoming
existing fragmentation and duplication of
research in Europe by establishing sustainable
cross-border networks.
Another area of action is the promotion of large
scale clinical trials, health economic analyses and
models for preventive and predictive care. In
addition, investing in research outcomes to
validate the effectiveness and speed up the
application of novel products, tools and
approaches in healthcare systems will be
Prof Dr Johan De Sutter, MD, PhD, FESC
Acting Chairman of the European Chronic DiseaseAlliance
European Society of Cardiology
Department Of Cardiology, AZMaria Middelares Gent and
Ghent University, Belgium
2 0 2 0
H O R I Z O N 2 0 2 0 P R O J E C T S : P O R TA L
H E A L T H : D I S E A S E R E S E A R C H
Prevention must
receive more
investment, says
the ECDA
1...,165,166,167,168,169,170,171,172,173,174 176,177,178,179,180,181,182,183,184,185,...244
Powered by FlippingBook